$KITE Kite Pharma, Inc. Insider Trading Week 24/2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. in week 24/2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 157,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 58.04 | 3,095 | 179,634 | 5,218 | 8.3 K to 5.2 K (-37.23 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 56.88 | 3,295 | 187,420 | 8,313 | 11.6 K to 8.3 K (-28.39 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 55.93 | 2,610 | 145,977 | 11,608 | 14.2 K to 11.6 K (-18.36 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 14,218 | 5.2 K to 14.2 K (+172.48 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | P | 17.00 | 4,000 | 68,000 | 5,218 | 1.2 K to 5.2 K (+328.41 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 292,300 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 58.04 | 2,541 | 147,480 | 6,000 | 8.5 K to 6 K (-29.75 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 56.93 | 2,726 | 155,191 | 8,541 | 11.3 K to 8.5 K (-24.19 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.93 | 2,433 | 136,078 | 11,267 | 13.7 K to 11.3 K (-17.76 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | P | 17.00 | 4,000 | 68,000 | 6,000 | 2 K to 6 K (+200.00 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 180,866 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 58.02 | 3,367 | 195,353 | 1,695 | 5.1 K to 1.7 K (-66.52 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 56.86 | 3,309 | 188,150 | 5,062 | 8.4 K to 5.1 K (-39.53 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 55.92 | 2,891 | 161,665 | 8,371 | 11.3 K to 8.4 K (-25.67 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 11,262 | 1.7 K to 11.3 K (+564.42 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 8,625 | 6,038 | 132,750 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 58.05 | 2,703 | 156,909 | 999 | 3.7 K to 999 (-73.01 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 56.93 | 3,345 | 190,431 | 3,702 | 7 K to 3.7 K (-47.47 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 55.94 | 2,577 | 144,157 | 7,047 | 9.6 K to 7 K (-26.78 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 8,625 | 6,038 | 9,624 | 999 to 9.6 K (+863.36 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 |